Neurogene Inc. (NGNE)

Market Cap	228.87M
Revenue (ttm)	925,000
Net Income (ttm)	-75.14M
Shares Out	14.93M
EPS (ttm)	-4.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	165,550
Open	16.22
Previous Close	16.14
Day's Range	14.81 - 16.64
52-Week Range	13.47 - 74.49
Beta	n/a
Analysts	Strong Buy
Price Target	59.80 (+290.09%)
Earnings Date	Mar 24, 2025

About NGNE

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquarter...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 91
• Stock Exchange: NASDAQ
• Ticker Symbol: NGNE
• Website: https://www.neurogene.com

Analyst Forecast

According to 5 analysts, the average rating for NGNE stock is "Strong Buy." The 12-month stock price forecast is $59.8, which is an increase of 290.09% from the latest price.

Price Target

$59.8

(290.09% upside)

Analyst Consensus: Strong Buy